In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia
暂无分享,去创建一个
[1] G. Riess,et al. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals. , 1995, The Journal of antimicrobial chemotherapy.
[2] B. Guery,et al. Should Pseudomonas aeruginosa isolates resistant to one of the fluorinated quinolones be tested for the others? Studies with an experimental model of pneumonia , 1995, Antimicrobial agents and chemotherapy.
[3] R. Gaynes,et al. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. , 1994, The Journal of infectious diseases.
[4] B. Tümmler,et al. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. , 1994, The Journal of infectious diseases.
[5] H. Richet,et al. Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. , 1994, The Journal of infectious diseases.
[6] S. Mitsuhashi,et al. Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa , 1994, Antimicrobial Agents and Chemotherapy.
[7] R. Davis,et al. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. , 1994, Drugs.
[8] M. Berant,et al. Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pigs: comparison of aerosol and systemic administration. , 1993, The Journal of infectious diseases.
[9] H. Grundmann,et al. Pseudomonas aeruginosa in a neonatal intensive care unit: reservoirs and ecology of the nosocomial pathogen. , 1993, The Journal of infectious diseases.
[10] M. Kaku,et al. Mortality rates amongst mice with endogenous septicaemia caused by Pseudomonas aeruginosa isolates from various clinical sources. , 1993, Journal of medical microbiology.
[11] C. Wood. Quinolone resistance: a practical perspective. , 1993, Archives of internal medicine.
[12] B. Foleno,et al. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin , 1992, Antimicrobial Agents and Chemotherapy.
[13] S. Miyazaki,et al. New quinolones--in vivo antibacterial activity. , 1992, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[14] D. Collett. Modelling Binary Data , 1991 .
[15] K. Mayer,et al. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. , 1991, The Journal of infectious diseases.
[16] J. Guinea,et al. In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone , 1991, Antimicrobial Agents and Chemotherapy.
[17] T. Nishino,et al. In-vitro and in-vivo activity of DR-3355, an optically active isomer of ofloxacin. , 1990, The Journal of antimicrobial chemotherapy.
[18] J. Waitz. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .
[19] P. Fernandes,et al. Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. III. Microbiologic profile. , 1989, The Journal of antibiotics.